ライフサイエンスコーパス: CD40

1 CD40 agonists bind the CD40 molecule on antigen-presenti

2 CD40 also stimulated autophagy via a pathway that includ

3 CD40 caused AMPK phosphorylation at its activating site,

4 CD40 deficiency impairs this process and prevents diabet

5 CD40 facilitates, but is not required for, development o

6 CD40 interacts with CD40L and plays an essential role in

7 CD40 is an important stimulator of autophagy and autopha

8 CD40 ligand (CD40L) deficiency predisposes to opportunis

9 CD40 ligand (CD40L), a member of the tumor necrosis fact

10 CD40 ligand- and Toll-like receptor 9-mediated signaling

11 CD40 ligation caused biphasic Jun N-terminal protein kin

12 CD40 ligation in Muller cells triggered phospholipase C-

13 CD40 signaling also inhibits the early unfolded protein

14 CD40 signaling during B cell activation is known to inhi

15 CD40 triggered AMPK-dependent Ser-555 phosphorylation of

16 CD40, a member of the tumour necrosis factor receptor (T

17 CD40-mediated autophagic killing of Toxoplasma gondii is

18 s identify a PPARgamma-dependent miR-424/503-CD40 signaling axis that is critical for regulation of i

19 PG102 induced the formation of a CD40 signaling complex that contained decreased amounts

20 mmatory responses in myeloid cells through a CD40-ATP-P2X7 pathway.

21 Gemcitabine in combination with a CD40 agonist induced T-cell-dependent regression of subc

22 lated surface expression of HLA-DR, HLA-ABC, CD40, CD80, CD83, and CD86, induced naive alphabeta T-ce

23 LMP2A, which mimic constitutively activated CD40 receptor and B-cell receptor signaling, respectivel

24 otein 1 (LMP1), mimics constitutively active CD40 and is essential for outgrowth of EBV-transformed B

25 Here, the effects of constitutively active CD40 in DCs on atherosclerosis were examined using low-d

26 percentages of B cells producing IL-10 after CD40 ligation and higher expression of CD40L on activate

27 aft maintained higher IL-10 production after CD40 ligation, which correlates with lower CD86 expressi

28 ressed higher levels of IL-10 receptor after CD40 engagement compared to other B-cell subsets.

29 function as a competitive antagonist against CD40 activation.

30 Agonistic CD40 mAb promotes stromal degradation and, in combinatio

31 omposite vaccination, including an agonistic CD40 antibody, soluble antigen, and a TLR3 agonist, refe

32 production by B cells was due to an altered CD40 and/or BCR signalling.

33 nt plasma cell (PC) generation, and although CD40 signaling is known to inhibit Blimp-1 induction dur

34 lation was completely blocked by CC-115, and CD40-mediated resistance to fludarabine and venetoclax c

35 g cells obtained by Toll-like receptor 9 and CD40 activation of B cells prevented TFH cell developmen

36 asmablasts, via the release of IFN-alpha and CD40 engagement.

37 ts were isolated from blood of apoE(-/-) and CD40(-/-)apoE(-/-) mice, respectively.

38 ound unique cellular requirements for B7 and CD40 expression in primary GC responses to vaccine immun

39 t, no requirement for coexpression of B7 and CD40 on the same cell in these responses.

40 Blocking of costimulatory CD28/B7 and CD40/CD40L interactions is an experimental approach to i

41 itic cells (DCs), in the presence of B7- and CD40-dependent co-stimulatory pathways.

42 rucial and distinct contributions of B7- and CD40-dependent pathways expressed by different APC popul

43 Akt/S6 kinase signaling pathway upon BCR and CD40 stimulation.

44 of DEC205 (CD205), Clec9A, CD11c, CD11b, and CD40 endocytosis and obtained quantitative measurements

45 he expression of the B cell markers CD23 and CD40, which are important for B cell differentiation int

46 ells restored normal expression of CD40L and CD40-murine IgG Fc fusion protein (CD40-muIg) binding, a

47 amma induces HLA class II, HLA-DM, CD80, and CD40 expression on MCs, whereas MCs take up soluble and

48 Ag presentation on MHC I molecules, CD86 and CD40 expression, and the production of IL-12 p70, IL-2,

49 mouse model humanized for its FcgammaRs and CD40, we revealed that FcgammaRIIB engagement is essenti

50 s (DCs) had reduced expression of MHC-II and CD40 compared with MKP-2(+/+) mice.

51 at their emergence required MHC class II and CD40/CD40L interactions.

52 Cognate T-B cell interactions and CD40-CD154 costimulation are essential for productive hu

53 VEGF, TIMP3, TIMP4, MMP13, ITGA2, ITGA3 and CD40, which promoted collagen synthesis, deposition and

54 actor, Toll-like receptor (TLR) ligands, and CD40 ligand.

55 TK and IkappaB kinase alpha in MCL lines and CD40-dependent B cells, with downstream loss of MAPK and

56 cells by exposure to lipopolysaccharide and CD40 ligand is not sufficient to trigger virus reactivat

57 Lipopolysaccharide- and CD40 ligand-induced maturation of iLC derived from laten

58 ding lymphotoxin-beta receptor (LTbetaR) and CD40.

59 t and inhibitors of B7-related molecules and CD40, blockade of B cell function and B cell survival fa

60 BCR, B cell-activating factor receptor, and CD40 coreceptor programs, leading to broadly enhanced po

61 L3 risk haplotype is correlated with TNF and CD40 induced NF-kappaB activation in primary human cells

62 optive transfers of polyclonal wild-type and CD40-deficient CD8(+) T cells into wild-type and CD40-de

63 -deficient CD8(+) T cells into wild-type and CD40-deficient hosts, we evaluated the contributions to

64 Wild-type and CD40-deficient platelets were isolated from blood of apo

65 Anti-CD40 treatment 2 or 3 d before chemotherapy resulted in

66 Anti-CD40/CpG + IC/anti-CTLA-4 synergistically induced regres

67 tion of omalizumab did not enhance IL-4/anti-CD40-induced IgE production in vitro.

68 of omalizumab on IgE production by IL-4/anti-CD40-treated PBMCs from allergic patients were studied i

69 n factor activation by CD154 or agonist anti-CD40 mAbs.

70 Conversely, administering agonist anti-CD40 monoclonal antibody to LNG-treated mice at 1 dpi re

71 licensing stimuli, such as an agonistic anti-CD40 antibody or Toll-like receptor 3 ligand.

72 ivation of dendritic cells by agonistic anti-CD40 antibody was compromised in chronically infected mi

73 ously shown the synergy of an agonistic anti-CD40 mAb (anti-CD40) and CpG-oligodeoxynucleotides in ac

74 -1R inhibition) or stimulate (agonistic anti-CD40 or inhibitory anti-CD47 antibodies) tumour-associat

75 ies collected from monkey dosed with an anti-CD40 antibody.

76 metry (FACS) and cultured with IL-4 and anti-CD40 to induce CSR to IgE.

77 e cultured tonsil B cells with IL-4 and anti-CD40.

78 n B-cells were stimulated with IL-4 and anti-CD40.

79 vity to immune-stimulatory mAbs such as anti-CD40, -4-1BB, and -CD28.

80 Current clinical anti-CD40 biologic agents include both antagonist molecules f

81 st immunization via NYVAC-KC and either anti-CD40.Env gp140/poly-ICLC or anti-LOX-1.Env gp140/poly-IC

82 Following anti-CD40 stimulation, IgD(-)IgM(+/low) B cells were blocked

83 hase II study testing ASK1240, that is, anti-CD40 antibody has been completed, and the results are pe

84 synergy of an agonistic anti-CD40 mAb (anti-CD40) and CpG-oligodeoxynucleotides in activating macrop

85 o antitumor activity of agonistic mouse anti-CD40 monoclonal antibodies (mAbs), a similar requirement

86 estigate alterations in the sequence of anti-CD40 and chemotherapy as an approach to enhance pharmaco

87 We suggest that a combination of anti-CD40/CpG and IC/anti-CTLA-4 should be developed for clin

88 Although the antitumor effect of anti-CD40/CpG did not require T cells, the antitumor effect o

89 or preclinical investigation of optimal anti-CD40 treatment regimens for safe design of clinical tria

90 Partnering anti-CD40 with different treatments is an attractive approach

91 ut did spontaneously, and upon LPS plus anti-CD40 stimulation, produce more TGF-beta than CD19(+) B c

92 y, despite our previous studies showing anti-CD40 treatment after chemotherapy is safe in both mice a

93 ith PDA, we report in this article that anti-CD40 administration <3 d in advance of chemotherapy is l

94 GD2(+) B78 melanoma model, we show that anti-CD40/CpG treatment led to upregulation of T cell activat

95 ASKP1240, the most advanced of the anti-CD40 antibodies targeting the CD40/CD154 costimulatory p

96 flammatory monocyte accumulation in the anti-CD40 innate colitis model through marked production of G

97 endritic cell morphology in response to anti-CD40 plus IL-4 were impaired in Cdc42-deficient B cells

98 with a number of clinical trials using anti-CD40 combinations ongoing, but the optimal therapeutic r

99 t the optimal therapeutic regimens with anti-CD40 are not well understood.

100 The combined treatment with anti-CD40/CpG + IC/anti-CTLA-4 reduced T regulatory cells in

101 zed that activation of macrophages with anti-CD40/CpG, and NK cells with IC, would cause innate tumor

102 uired for, development of severe TEC H/P, as CD40(-/-)IFN-gamma(-/-)CD28(-/-) mice develop severe TEC

103 nd costimulatory signaling pathways, such as CD40 or TLRs.

104 LLT1 expression was readily induced via BCR, CD40, and CpG stimulation on B cells.

105 Blockade of the interaction between CD40 and CD40L induces long-term cardiac allograft survi

106 mmuno-oncology, yet the relationship between CD40 epitope and these opposing biological outcomes is n

107 Blocking CD40-CD40L costimulatory signals induces transplantation

108 lper functions of memory CD4 T cells in both CD40(-/-) recipients and wild type recipients treated wi

109 ation and thrombus formation, involving both CD40-dependent and -independent mechanisms.

110 viduals showed increased frequencies of both CD40(+) and IL-10(+) B cells compared to T1D patients.

111 potential between soluble and membrane-bound CD40 agonists.

112 enovirus encoding a chimeric, membrane-bound CD40 ligand (ISF35).

113 resulted in increased production of IL-12 by CD40-stimulated DC.

114 Proliferation induced by CD40(+) interleukin-21 stimulation was completely blocke

115 iquitous TNFRSF receptor(s) cross-linking by CD40 and Fas agonistic antibodies resulted in dose-limit

116 In this model, CD154/CD40 axis blockade using IDEC-131 is an inferior immunom

117 t CD10), a B-cell immunophenotype (CD19/CD20/CD40(+)), IgD and/or IgM expression (67%), and lack of p

118 Frequency of CD38, CD40 and type I interferon high responders was significa

119 s (TRAFs) plays key roles in mediating CD40L-CD40 signaling.

120 t patients reveal the critical role of CD40L-CD40 interaction for the function of T, B, and dendritic

121 apoptosis in CLL by suppressing BCR, CD49d, CD40, and Toll-like receptor 9-mediated AKT activation i

122 h the frequency of activated B cells (CD86(+)CD40(+)) reduced compared with pre-ART levels (p = 0.000

123 ility to CD40 killing, while in normal cells CD40 signalling is cytoprotective.

124 Direct stimulation of complex component CD40 on DCs leads to activation of Akt1, suggesting CD40

125 /CD40 fusion protein conferring constitutive CD40 signaling under control of the DC-specific CD11c pr

126 They also show that constitutive CD40 signaling in vivo involving bystander T-B interacti

127 immunodepression favoring cryptosporidiosis (CD40 ligand deficiency [n = 1], human immunodeficiency v

128 eptors, namely the BCR, BAFFR, CXCR4, CXCR5, CD40, and TLR4, were impaired in promoting CD19 co-recep

129 A similarly selected anti-cynomolgus CD40 dAb recognizing the homologous epitope is also a po

130 lls, with stimulation via the BCR decreasing CD40-mediated IL-10 production.

131 uggesting a requirement for IFN-gamma during CD40-independent help.

132 cative of DC activation and maturation, i.e. CD40, CD86, and MHC class II.

133 PG102 did not induce early CD40-induced signaling events, and it inhibited early ki

134 structural requirements needed for efficient CD40-CD40L inhibition, and serve to guide the search for

135 These vaccines bind to either CD40 or LOX-1, two dendritic cell surface receptors with

136 HIV-1 envelope protein (Env gp140) to either CD40 or LOX-1, two endocytic receptors on dendritic cell

137 mmatory stimuli led to increased endothelial CD40 expression, at least in part due to decreased miR-4

138 microRNA mediated suppression of endothelial CD40 expression.

139 previously showed that the parasite enhanced CD40-induced Raf-MEK-ERK signaling but inhibited PI3K-MK

140 proliferating thyrocytes that highly express CD40.

141 epends on the presence of B cells expressing CD40 and intact CD40/CD154 interactions.

142 the reduced phosphorylation of P65 following CD40 stimulation in treated patients.

143 f phosphorylated NF-kappaB (p-P65) following CD40 stimulation compared with healthy donor controls.

144 Assessment of downstream signaling following CD40 cross-linking in the presence or absence of SLAM cr

145 CaMKKbeta, AMPK, and ULK1 were required for CD40-induced increase in autophagy.

146 To determine cytokine requirements for CD40-independent help, we used CD40(-/-) mice containing

147 pically similar population of CD4(+) Foxp3+, CD40 ligand-positive T cells was found in diseased liver

148 As including miR-363 within EVs derived from CD40/IL-4-stimulated CLL cells compared with parental ce

149 CD4(+) T cells that are exposed to EVs from CD40/IL-4-stimulated CLL cells exhibit enhanced migratio

150 is, we find that naive B cells purified from CD40-CD154 interaction-deficient mice express higher amo

151 It required CD4 T cell help, CD40 signaling and CD28-based costimulation during allos

152 It remains undetermined whether and how CD40 on DCs impacts the pathogenesis of atherosclerosis.

153 However, CD40 did not cause TNF-alpha or IL-1beta secretion in Mu

154 e demonstrate that the antagonist anti-human CD40 mAb PG102 fails to trigger CD40-mediated activation

155 ential of antagonist mAbs specific for human CD40.

156 antibodies (dAbs) that bind to a novel human CD40-specific epitope that is divergent in the CD40 of n

157 ement is essential for the activity of human CD40 mAbs, while engagement of the activating FcgammaRII

158 AMPK, or ULK1 prevented T. gondii killing in CD40-activated macrophages.

159 rotid artery wire injury reduces markedly in CD40(-/-) apolipoprotein E-deficient (apoE(-/-)) mice bu

160 L. major infection in BALB/c mice but not in CD40-deficient mice.

161 icient (apoE(-/-)) mice but only slightly in CD40 ligand(-/-)apoE(-/-) mice, compared with apoE(-/-)

162 l cerebral malaria mortality and symptoms in CD40-KO recipients, indicating platelets elicit pathogen

163 ng through B-lymphocyte receptors, including CD40, BAFF receptor, and Toll-like receptors, and also p

164 MDC are rendered nonprotective by increasing CD40 expression and phosphorylation of p65 NF-kappaB.

165 5, a potent growth factor for ILC3s, induced CD40 ligand (CD40L) expression on circulating and tonsil

166 mmunity to liver stage Plasmodium infection, CD40 was critical for the full maturation of liver dendr

167 The inflammatory CD40-CD40L pathway is implicated in various autoimmune d

168 e physical competition with CD154 to inhibit CD40 signaling have particular therapeutic promise.

169 esence of B cells expressing CD40 and intact CD40/CD154 interactions.

170 jection of thrombin-activated platelets into CD40(-/-)apoE(-/-) mice was performed every 5 days, star

171 stemic antitumor activity after intratumoral CD40 triggering with ISF35 in combination with checkpoin

172 s, and their suppressive activities involved CD40, CD80, CD86, and intercellular adhesion molecule in

173 regulated their activation markers, that is, CD40, CD80, CD86, and MHC class II molecules.

174 ing the expansion of this population and its CD40 expression, while lowering its CD134 expression, th

175 expression of CD40LG and active full-length CD40 was increased in the disease tissues, whereas that

176 n engineered latent membrane protein 1 (LMP)/CD40 fusion protein conferring constitutive CD40 signali

177 Moreover, DC-LMP1/CD40 chimeras developed inflammatory bowel disease chara

178 sed by 37% and 60%, respectively, in DC-LMP1/CD40 chimeras.

179 ed, DC-LMP1/CD40/Ldlr(-/-) chimeras (DC-LMP1/CD40) showed increased antigen-presenting capacity of DC

180 l of the DC-specific CD11c promoter (DC-LMP1/CD40).

181 As expected, DC-LMP1/CD40/Ldlr(-/-) chimeras (DC-LMP1/CD40) showed increased

182 etry and the expression of activation marker CD40 ligand by CD4(+)T cells.

183 ility to upregulate the costimulatory marker CD40, suggesting IDO2 acts at the T-B cell interface to

184 was positive for the co-stimulatory markers CD40, CD80 and CD86, but both demonstrated increased lev

185 ctivation, as well as impairs CD154-mediated CD40 activation, via a distinct nonstimulatory CD40 sign

186 tent membrane protein 1 (LMP1) (which mimics CD40 signaling), and EBV-encoded nuclear antigen 3A (EBN

187 The costimulatory molecule CD40 enhances immunity through several distinct roles in

188 The costimulatory molecule CD40 is a major driver of atherosclerosis.

189 MHC class II and the costimulatory molecule CD40 on the surface of the cells.

190 urface expression of costimulatory molecules CD40 and CD86 in DCs and promoted increased T cell proli

191 marker CD83 and the costimulatory molecules CD40, CD80, and CD86, decreased production of key proinf

192 en D related and the costimulatory molecules CD40, CD80, and CD86.

193 of MHC class II and costimulatory molecules (CD40, CD86) expression as well as proinflammatory cytoki

194 Higher basal amounts of Blimp-1 in naive CD40(-/-) B cells correlate with an increased tendency o

195 tissues, whereas that of a dominant-negative CD40 isoform was decreased.

196 40 activation, via a distinct nonstimulatory CD40 signaling mechanism.

197 ival of colorectal cancer patients and NOS2, CD40, and TNF expression in their tumors.

198 Constitutive activation of CD40 in DCs results in inflammation of the gastrointesti

199 In vivo blockade of CD40 ligand attenuated B-cell abnormalities in a mouse m

200 Because blockade of CD40-CD40L interactions results in tolerance in mice, id

201 naive B cells ex vivo with a combination of CD40 ligand and interleukin 4.

202 JNK signaling downstream of CD40 caused Ser-87 phosphorylation of Bcl-2 and dissocia

203 mponents of signaling pathways downstream of CD40 engagement in B cells from MS patients.

204 Most of the effects of CD40 could be accounted for by expression in the T cells

205 s have a survival defect after engagement of CD40 or Toll-like receptors (TLR), despite paradoxically

206 ivities were maintained due to expression of CD40 ligand on a subset of CD4(+) Foxp3+ T cells.

207 This allele diminishes the expression of CD40, a co-stimulatory molecule for T cell polarization.

208 nd naive B cells to assess the expression of CD40-downstream genes in synovial tissues from anti-citr

209 e contributions to CD8(+) T cell immunity of CD40 expressed on host tissues including APC, compared w

210 Blocking the interaction of CD40 with its ligand CD154 is a desirable goal of therap

211 ctivated platelets were abrogated by lack of CD40 on injected platelets.

212 ut this effect was also abrogated by lack of CD40 on injected platelets.

213 more type 1 IFN and express higher levels of CD40, and NOD monocyte DCs make more TNF.

214 This was associated with decreased levels of CD40, HLA-DR, and CD86 expression on DCs and increased e

215 ipts, suggesting that noncognate ligation of CD40 via T-B interactions may repress Blimp-1 in vivo.

216 Loss of CD40 ligand (CD40L) expression or function results in X-

217 These studies highlight the dual nature of CD40 in activating both macrophages and T cell responses

218 rs1883832, in the 5'-untranslated region of CD40, was associated with earlier LoA (p = 3.5 x 10(-5))

219 n, and suppress LPS-induced up-regulation of CD40 and CD86.

220 dings, however, support a pathogenic role of CD40 in a number of autoimmune diseases.

221 teract with CD4 T cells (the major source of CD40 ligand).

222 olecular nature of the tumour specificity of CD40 signalling and explained the differences in pro-apo

223 te that the epitope is distinct from that of CD40 agonists.

224 Nevertheless, upregulation of CD40 and CD86 in cDCs was critically influenced or even

225 Upregulation of CD40, CD80, CD83, and CD86 on monocyte-derived dendritic

226 ve cell-to-cell contact that is dependent on CD40-CD40 ligand (CD40L) interactions; and (iv) fully ac

227 C57BL/6 donors but not from MHC class II- or CD40-deficient donors.

228 g platelets elicit pathogenesis and platelet CD40 is a key molecule.

229 Results suggest that platelet CD40 plays a pivotal role in neointima formation after a

230 red simultaneously at approximately 4 h post-CD40 stimulation.

231 tosis is only achieved by membrane-presented CD40 ligand (mCD40L), as soluble receptor agonists are b

232 ortantly, increased levels of Breg-promoting CD40(+) B cells and IL-10-producing B cells were found w

233 CD40L and CD40-murine IgG Fc fusion protein (CD40-muIg) binding, and rescued IgG class switching of n

234 nner mediated by the co-stimulatory receptor CD40.

235 included cluster of designation 40 receptor (CD40), epithelial-derived neutrophil-activating protein

236 rug engagement of a membrane bound receptor (CD40) that is critical to immune regulation in colon bio

237 ment prior to infection dramatically reduced CD40 expression in DCs isolated from draining lymph node

238 acetate treatment also significantly reduced CD40-mediated P65 phosphorylation in RRMS patients, sugg

239 n in RRMS patients, suggesting that reducing CD40-mediated p-P65 induction may be a general mechanism

240 Fab fragments of PG102, while retaining CD40 binding, did not induce TRAF degradation, nor could

241 Soluble CD40 ligand (sCD40L) has been implicated in the developm

242 natriuretic peptide, interleukin-6, soluble CD40 ligand, and insulin-like growth factor binding prot

243 a under the curve (AUC) for IL-6 and soluble CD40 ligand (sCD40L) and chronic viremia was observed on

244 in vitro effects of rhIFN-gamma and soluble CD40 ligand (sCD40L) treatment on macrophages.

245 e chemotactic protein-1 (MCP-1), and soluble CD40 ligand were also observed in the experimental group

246 m Cd40(-/-) mice and were rescued by soluble CD40.

247 ombinatorial treatment incorporating soluble CD40 agonist and pharmacological inhibition of Trx-1 was

248 F [epidermal growth factor], sCD40L [soluble CD40 ligand], PDGF [platelet-derived growth factor], RAN

249 Strikingly, CD40 activation resulted in down-regulation of Thioredox

250 Strikingly, CD40 signaling in the absence of BCR- or TLR-ligation al

251 DCs leads to activation of Akt1, suggesting CD40 involvement in anti-apoptotic effects observed.

252 We found that CD40 is closely regulated by miR-424 and miR-503, which

253 Our studies indicate that CD40 in Muller cells is sufficient to upregulate retinal

254 stimulated B cell signaling, indicating that CD40 aggregation is required for the signaling inhibitio

255 We report that CD40 signaling induces miR-125b that targets Blimp-1 tra

256 Here we show that CD40, a member of the TNF receptor superfamily, is a maj

257 The data show that CD40-mediated inhibition of PC generation is via engagem

258 These results suggest that CD40-activated CD40L reverse signalling has striking and

259 The CD40 decoy receptor, sCD40R, may serve as a potential th

260 The CD40 receptor exists in a soluble form, sCD40R, and has

261 The CD40/CD40 ligand dyad in endothelial cells (EC) has a ce

262 ion indicated that the fibrils activated the CD40/B-cell receptor pathway in B-1a cells and induced a

263 3 monoclonal antibodies directed against the CD40/CD154 T cell costimulation pathway.

264 ivating endogenous host CD103(+) DCs and the CD40-CD40L pathway can similarly induce rapid accumulati

265 healthy volunteers, the balance between the CD40 and B-cell receptor (BCR) signalling modulated IL-1

266 CD40 agonists bind the CD40 molecule on antigen-presenting cells and activate t

267 In addition, research into blocking the CD40-CD154 pathway is underway.

268 lpha and JNK signaling were required for the CD40-induced increase in autophagy.

269 40-specific epitope that is divergent in the CD40 of nonhuman primates.

270 on of novel small-molecule inhibitors of the CD40-CD40L interaction designed starting from the chemic

271 The safety and efficacy of the CD40-targeted vaccine justify further development for fu

272 Tumor elimination via NOS2 required the CD40-CD40L pathway.

273 ed of the anti-CD40 antibodies targeting the CD40/CD154 costimulatory pathway has just completed a ph

274 onclusion, our data suggest that therapeutic CD40-CD40L blocking agents may prove efficacious not onl

275 necrosis factor (TNF) superfamily, binds to CD40, leading to many effects depending on target cell t

276 BAFF stimulation, in contrast to CD40 activation, was unable to rescue relb/nfkb2-deleted

277 Overall, targeting Env to CD40 gave more robust T cell and serum antibody response

278 Conversely, a 24-h exposure to CD40 ligation during LPS stimulation of wild-type B cell

279 nd regulated the sensitivity of NF-kappaB to CD40 stimulation in B cells and TNF stimulation in monoc

280 cation, adoptive transfer of WT platelets to CD40-KO mice, which are resistant to experimental cerebr

281 tive transfer of wild-type (WT) platelets to CD40-KO mice, which do not control parasite replication,

282 Knockdown of miR-363 in CLL cells prior to CD40/IL-4 stimulation prevented the ability of CLL-EVs t

283 nocytes, as well as NF-kappaB sensitivity to CD40 or tumour necrosis factor (TNF) stimulation.

284 h coincides with increased susceptibility to CD40 killing, while in normal cells CD40 signalling is c

285 t anti-human CD40 mAb PG102 fails to trigger CD40-mediated activation, as well as impairs CD154-media

286 uirements for CD40-independent help, we used CD40(-/-) mice containing differentiated subsets of dono

287 atched healthy volunteers were activated via CD40 and BCR, either alone or in combination.

288 vaccines, but especially that delivered via CD40, raised robust immunity against HIV-1 as measured b

289 DCs but was not required on B cells, whereas CD40 was required on B cells but not on DCs in the gener

290 ers survival and antibody secretion, whereas CD40 costimulation with IL-21 or IFN-gamma promotes a T-

291 nd TNF-alpha are upstream molecules by which CD40 acts on ULK1 and Beclin 1 to stimulate autophagy an

292 we studied the molecular mechanisms by which CD40 stimulates autophagy in macrophages.

293 on host tissues including APC, compared with CD40 expressed on the CD8(+) T cells themselves.

294 mice (8 to 10 weeks old) were cultured with CD40 ligand (CD40L) and the Toll-like receptor 9 (TLR9)

295 During diabetes, mice with CD40 expressed in Muller cells upregulated retinal tumor

296 Using mice with CD40 expression restricted to Muller cells, we identifie

297 cted in Muller cells from diabetic mice with CD40(+) Muller cells.

298 tients exhibited enhanced proliferation with CD40 stimulation compared with healthy donors.

299 ing with this, combining BCR signalling with CD40 ligation did not reduce IL-10 secretion as was obse

300 EVs released from CLL cells stimulated with CD40 and interleukin-4 (IL-4).